Nasal-to-CNS Drug Delivery: Where are We Now and Where are We heading? an Industrial Perspective

Abstract

Delivery of drug therapeutics across the blood–brain barrier is a challenging task for pharmaceutical scientists. Nasal-to-CNS drug delivery has shown promising results in preclinical efficacy models and investigatory human clinical trials. The further development of this technology with respect to the establishment of valid, predictable preclinical species models, translatable pharmacokinetic–pharmacodynamic relationships and definition of toxicology impact will help attract additional pharmaceutical investment in this drug-delivery approach. Further discoveries in nasal nanotechnology, targeted delivery devices and diagnostic olfactory imaging will serve to fuel the advancements in this area of drug delivery.

Financial & competing interests disclosure

The authors of this manuscript are currently employed by Pfizer Global Research and Development. Pfizer Global Research and Development is not currently marketing an intranasal delivery technology to target CNS delivery. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.